STAAR SURGICAL CO. overview

Jimmy O. Yang Partners with STAAR Surgical to Shine a Light on Their Vision Correction Lens, EVO ICL PR Newswire LAKE FOREST, Calif., Oct. 10, 2023 LAKE FOREST, Calif. , Oct. 10, 2023 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, is proud to announce a partnership with renowned actor and comedian, Jimmy O. Yang . This partnership brings together EVO Implantable Collamer ® Lenses (EVO ICL) for...

Dolby Laboratories Set to Join S&P MidCap 400; Staar Surgical to Join S&P SmallCap 600 PR Newswire NEW YORK, Aug. 17, 2023 NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Dolby Laboratories Inc. (NYSE:DLB) will replace Staar Surgical Co. (NASD:STAA) in the S&P MidCap 400 and Staar Surgical will replace Urstadt Biddle Properties Inc. (NYSE:UBA) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, August 22 . S&P 500 constituent Regency Centers Corp. (NASD: REG) will acquire...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced its partnership with Will Levis, quarterback for the Tennessee Titans of the National Football League (NFL). This partnership will raise awareness of the EVO Implantable Collamer ® Lenses (EVO ICL) . The EVO ICL is a vision correction device that works in harmony with your natural eye, provides clear vision 1,2 day or night 1,3 , and does not cause contact...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that management will participate in several upcoming investor conferences. STAAR management will participate in the following investor conferences: Canaccord Genuity Annual Growth Conference, Wednesday, August 9. Management Presentation and Q&A at 10:00 a.m. Eastern / 7:00 a.m. Pacific at the following link: https://wsw.com/webcast/canaccord89/staa/2452967...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency ICL Units Up 21% Y/Y Gross Margin at 76.6% vs. 78.8% in the Prior Year Quarter Net Income of...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second quarter ended June 30, 2023 on Wednesday, August 2, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, August 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 99981426),...

EVO ICL, the vision correction procedure that works in harmony with your natural eye, provides sharp, clear vision day or night and does not cause contact lens induced dry eye or dry eye syndrome, announced today sponsorship of the Jonas Brothers’ The Tour in North America, which begins August 12. Collaboration with the group will also include a new EVO advertising campaign slated for launch in the fall of 2023. The campaign will help drive education and awareness of EVO among the millions of...

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Overview Net Sales of $73.5 Million Up 16% and Constant Currency Net Sales of $75.5 Million Up 20% Y/Y ICL Sales of $70.6 Million Up 20% and Constant Currency ICL Sales of $72.4 Million Up 23% Y/Y ICL Units Up 20% Y/Y Gross Margin at 78.3% vs. 77.9% in the Prior Year Quarter Net...